CervoMed (CRVO) Stifel 2024 Healthcare Conference summary

Business and financial overview

• Company is developing oral therapeutics for neurodegenerative diseases, focusing on Dementia with Lewy Bodies (DLB).

• Leadership and advisory teams have extensive experience in drug development and clinical success.

• Over $46.7 million in cash and grant funding as of last quarter, with a cash runway through end of 2025.

• Additional $99.4 million in funding contingent on positive phase II-B results, supporting phase III trial launch in mid-2025.

• All milestones met since going public, with top-line results to be presented and published in early 2025.

Clinical program highlights

• Lead drug, neflamapimod, targets DLB, the third most common neurodegenerative disease after Alzheimer's and Parkinson's.

• Only company with positive phase II data in DLB, published in high-profile journals.

• Focused on early-stage DLB patients, representing about half of the 700,000 U.S. DLB cases.

• Phase II-A study showed significant improvements in dementia severity and motor function at optimal dosing.

• Phase II-B trial excludes advanced disease patients using p-Tau181 biomarker for a more homogeneous population.

Scientific and clinical rationale

• Drug mechanism targets p38 alpha protein, regulating disease processes in the basal forebrain cholinergic system.

• Demonstrated reversal of neurodegeneration and improved brain function in animal and human studies.

• Early-stage DLB patients show the greatest clinical benefit, including reversal of disease progression.

• Biomarker and imaging data support drug’s efficacy and mechanism of action.

• Clinical effects correlate with reductions in neurodegeneration biomarkers, supporting proof of concept.